X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Biosimilar Space Disruption Lead By Novartis And Pfizer

Content Team by Content Team
27th January 2022
in News
DNA

As per GlobalData’s Thematic Research ecosystem, pharmaceutical giants Novartis and Pfizer are the best-positioned companies to take advantage of future biosimilars in the pharma landscape. This ecosystem by GlobalData positions companies on a one to five scale, predominantly on the basis of how they would tackle challenges like the ones in biosimilars and come out as long-term winners in the pharmaceutical spectrum. The analysis shows that companies like Novartis, Pfizer, Viatris, Amgen, Catalent, Celltrion, Patheon, Shanghai Henlius, and Samsung Bioepis are currently best placed to get the maximum benefit from biosimilar investments. Notably, they all received a five out of five in GlobalData’s drug development thematic score analysis.For instance, Novartis has promoted 406 new biosimilar positions in the last calendar year and denoted biosimilars in the company’s filings at least 119 times.

Pfizer, on the other hand, has an impressive AI investment and the company is looking for 101 new biosimilar jobs from January 2021 while completing one deal and mentioning biosimilars 80 times as far as filings are concerned. As per the table, GlobalData has cited the biggest companies in the pharmaceutical landscape when it comes to their biosimilar performance and also the number of biosimilar jobs that have been rolled out by them in 2021.

The last column in the table signifies the total score given to that particular company based on its current biosimilar position vis-a-vis its contemporaries. The score of five represents that the company has been a dominant player in the biosimilar space, and the ones that have scored less than three are most likely to be left behind. The other datapoints in the table appear more nuanced, reflecting recent biosimilar investments in a variety of areas over the last year.The matrix is a pure reflection of whether biosimilars are on top of the executives’ minds or if they are just a desperate attempt to catch up with other players.

Just to cite an example, the high number of biosimilar mentions in the quarterly filings may either indicate that the company is looking to catch up with the industry or is already reaping the rewards. Besides, a high number of deals is indicative of a company’s dominance in the market or if it is using mergers and acquisitions as a tool to fill the gaps.

Previous Post

Moderna To introduce The Fusion Of COVID-19 And Flu Booster

Next Post

Biotech Companies In China Look To Have A Global Footprint

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Biotech Companies In China Look To Have A Global Footprint

Biotech Companies In China Look To Have A Global Footprint

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In